Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Turn Therapeutics Inc.NASDAQ: TTRX
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares of 29.48M shares in Q1 FY2026
Q1 FY2026 weighted avg shares was 29.48M shares. Trailing-twelve-month weighted avg shares was 25.17M shares.
Context
- Weighted avg shares increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly weighted avg shares holds near 29.48M shares or moves back toward the trailing-twelve-month quarterly average of 6.29M shares.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 13.74M USD
- Year-over-year change
- +2.4%
- 2-year CAGR
- +1.9%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.74M | +2.4% |
| FY2024 | 2024-12-31 | 13.42M | +1.3% |
| FY2023 | 2023-12-31 | 13.25M | — |
Weighted Avg Shares vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's LTM Mar 2026 weighted avg shares of 25.17M shares is the 8th highest of the 9 companies compared; the peer median is 53.88M shares.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
IRDOpus Genetics, Inc. | LTM Mar 2026 | 406.29M | +1283.9% | +214.9% |
| LTM Mar 2026 | 94.17M | +114.9% | +186.0% | |
| LTM Mar 2026 | 79.93M | +69.4% | +35.9% | |
| LTM Mar 2026 | 56.96M | -7.5% | -2.7% | |
| LTM Mar 2026 | 50.79M | +127.0% | +911.7% | |
| LTM Mar 2026 | 33.32M | +48.8% | +28.3% | |
| LTM Apr 2026 | 32.94M | +2.7% | +2.2% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | 25.17M | — | — |
| LTM Mar 2026 | 13.8M | +5.4% | +1.6% | |
| Peer median (excluding TTRX) | 53.88M | +59.1% | +32.1% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 7.5K | 245.96K | 265.57K |
| Selling, General & Admin | 2.3M | 1.55M | 5.59M |
| Operating Expenses | 2.31M | 1.8M | 5.86M |
| Depreciation & Amortization | 43.92K | 47.48K | 52.75K |
| EBITDA | (2.25M) | (1.72M) | (3.14M) |
| EBITDA Margin | — | — | — |
| Operating Income | (2.31M) | (1.8M) | (5.86M) |
| Operating Margin | — | — | — |
| Interest Income | 15.88K | 28.71K | 29.58K |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 15.88K | 28.71K | 2.66M |
| Income Before Tax | (2.29M) | (1.77M) | (3.19M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (2.29M) | (1.77M) | (3.19M) |
| Net Margin | — | — | — |
| EPS (Basic) | (0.17) | (0.13) | (0.23) |
| EPS (Diluted) | (0.17) | (0.13) | (0.23) |
| Weighted Avg Shares | 13.25M | 13.42M | 13.74M |
| Weighted Avg Shares (Diluted) | 13.25M | 13.42M | 13.74M |
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.